argenx SE

argenx: 3 Key Takeaways for Long-Term Investors

Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.

714 argenex SE $ARGX Shares Bought by Diversify Advisory Services LLC

argenx SE (ARGX) Q3 2026 Earnings Call Transcript

argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Paribas, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Jing Deng Sean Laaman - Morgan Stanley, Research Division Sophia Graeff Buhl Nielsen - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Douglas Tsao - H.C.

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

What argenex (ARGX) Said on Its Q3 Earnings Call

argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.